Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200015/S084

Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX)

Edwards Lifesciences, LLC · Decision date Oct 28, 2026

MEDTECHLEDGER EXPLANATIONP200015/S084

What did the FDA decide?

Edwards Lifesciences, LLC filed PMA supplement P200015/S084 for the SAPIEN 3 Transcatheter Heart Valve (9600TFX), a percutaneously delivered pulmonary valve prosthesis under product code NPV. The FDA record lists it as a 30-Day Notice with decision OK30, dated 2026-10-28. The supplement reason field cites a process change involving manufacturer, sterilizer, packager, or supplier, and the statement describes implementing an alternative supplier of a chemical manufacturing aid.

The supplement number ties this action to PMA P200015, but it is a notice about a supplier change, not an original approval of the valve system. The fields do not name the chemical manufacturing aid, the prior or replacement supplier, the affected manufacturing step, or any supporting data. The reported purpose does not by itself establish safety or clinical effectiveness, and no clinical or regulatory conclusion beyond this descriptive record is supported.

The available source does not specify which category—manufacturer, sterilizer, packager, or supplier—applies, nor identify the device component affected. Researchers should treat the stated purpose as the applicant's notice content rather than corroborated evidence of device performance.

FDA approval order statement

implementing an alternative supplier of a chemical manufacturing aid
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 28, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200015/S084
Regulatory pathway
PMA supplement
Product code
NPV
Decision code
OK30
Decision date
Oct 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pulmonary valve prosthesis percutaneously delivered.

Product code
NPV
FDA device class
f

For the original device and its historical approval scope, see PMA P200015. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200015 · Original PMA

    Edwards SAPIEN 3 Transcatheter Heart Valve System with Edwards Commander Delivery System

  2. P200015/S083 · Related supplement

    Edwards Crimper (9600LDS20, 9600LDS23, 9600LDS26, 9600LDS29)

  3. P200015/S084 received

    Application receipt date recorded by FDA.

  4. P200015/S077 · Related supplement

    SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent

  5. P200015/S084 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P200015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200015

Explore the linked device profile

Other records with product code NPV

Product / regulatory recordCompanyPathwayDecision dateSource
Harmony TPV SystemP200046/S052
Medtronic, Inc.PMA supplementSep 30, 2026FDA
Medtronic, Inc.PMA approvalMar 26, 2021FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records